About: http://data.cimple.eu/news-article/28992a4cf9b01fd5ca9257c2e76765f583252836e5858c585d63d14c

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: http://data.cimple.eu/news-article/28992a4cf9b01fd5ca9257c2e76765f583252836e5858c585d63d14c Goto Sponge NotDistinct Permalink

An Entity of Type : schema:NewsArticle, within Data Space : data.cimple.eu associated with source document(s)

Attributes	Values
rdf:type	schema:NewsArticle
schema:articleBody	Trials on the coronavirus vaccine developed by AstraZeneca and Oxford University have resumed in Japan but not the United States, where the pharmaceutical giant is working with regulators, a statement released Friday said. The Financial Times, citing sources close to the case, reported that the US drug regulator the FDA had expanded its investigation into the serious side effects suffered by one trial participant, which had led to a brief halt in the tests. The British company did not respond immediately to an AFP request for comments. "The Phase I/II clinical trial for the COVID-19 vaccine AZD1222 has resumed in Japan after discussion with the Japanese Pharmaceuticals and Medical Devices Agency," AstraZeneca said in a press release on Friday. It said it had triggered a "voluntary pause to vaccination across all global trials on 6 September to allow review of safety data by an independent committee". "Their recommendations have been supported by international regulators in the UK, Brazil, South Africa, India and now in Japan, who have deemed that the trials are safe to resume," the group said. It will "continues to work with the Food and Drug Administration (FDA) to facilitate review of the information needed to make a decision regarding resumption of the US trial," added the statement. Trials began at the end of August and group head Pascal Soriot said last month that the vaccine could still be ready by the end of the year, despite the setback. The vaccine is one of the most advanced Western projects, having already been tested on tens of thousands of volunteers worldwide. The World Health Organisation has identified 35 "candidate vaccines" being tested in human clinical trials around the world, with nine already in the final stage, or about to enter it. The European Medicines Agency (EMA) estimates that it could take until at least early 2021 for a vaccine against Covid-19 to be approved and available for global use. jwp/jj/adp
schema:headline	Leading Covid-19 vaccine trial resumes in Japan but not US
schema:mentions	Financial Times Medicines and Healthcare products Regulatory Agency Agence France-Presse European Medicines Agency Clinical trial Pharmaceutical industry Japanese language University of Oxford World Health Organization AstraZeneca Food and Drug Administration Japan South Africa India United Kingdom Brazil Vaccine United States Severe acute respiratory syndrome coronavirus 2 Coronavirus disease 2019 Pascal Soriot Adenosine diphosphate
schema:author	http://data.cimple.eu/organization/1f0054d541e000623a2c1e561a247c073ef6328e8be9ffafda7b3fcd
schema:datePublished	2020-10-02 (xsd:date)
http://data.cimple...sPoliticalLeaning	other political leaning
http://data.cimple...logy#hasSentiment	negative sentiment
http://data.cimple...readability_score	93 (xsd:integer)
http://data.cimple...tology#hasEmotion	happiness

Faceted Search & Find service v1.16.115 as of Oct 09 2023

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3238 as of Jul 16 2024, on Linux (x86_64-pc-linux-musl), Single-Server Edition (126 GB total memory, 3 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software